No Data
No Data
Guilin Sanjin Pharmaceutical (002275.SZ): The proportion of Sanjin Pills in the hospital is slightly higher than that of Xigua Frost.
Guilin Sanjin (002275.SZ) recently stated during a reception for institutional investors that the company mainly produces dual-use drugs, with varying proportions for each type. Overall, OTC drugs are the main focus, while prescription drugs are a secondary focus, accounting for approximately 80% and 20%, respectively. For the Watermelon Frost series, the proportion of OTC drugs is always higher than prescription drugs, approximately 80% to 20%, while the hospital usage of Sanjin Tablets is slightly higher than Watermelon Frost.
Guilin Sanjin Pharmaceutical (002275.SZ): From the perspective of the whole year, the company strives to complete this year's tasks according to the budget.
Guilin Sanjin (002275.SZ) stated during an investor relations event on June 20th that the company's first quarter performance declined compared to the same period last year mainly due to the impact of a public health event during the same period last year, which resulted in a significant increase in sales for the current period as a result of normal market supply. At the same time, excluding the impact of special circumstances from the first quarter of last year, the sales volume for the first quarter of 24, 22, 21 and previous years is also at a high level compared to the same period. The company also announced its budget for this year and aims to accomplish this year's tasks according to the budget for the whole year.
Guilin Sanjin Pharmaceutical (002275.SZ): The actual controller Zou Xun has passed the halfway mark of the shareholding period and has accumulated 148,300 shares.
On June 3, Gelonhui reported that Guilin Sanjin (002275.SZ) announced that as of June 1, 2024, the time for this shareholding plan had passed halfway. Mr. Zou Xun, the actual controller, chairman, and CEO of the company, has accumulated 148,300 shares of the company's stock through the Shenzhen Stock Exchange's centralized bidding trading, accounting for 0.03% of the company's existing total share capital, with a shareholding amount of 2.0472 million yuan.
Dividend Investors: Don't Be Too Quick To Buy Guilin Sanjin Pharmaceutical Co., Ltd. (SZSE:002275) For Its Upcoming Dividend
Guilin Sanjin Pharmaceutical Co., Ltd. (SZSE:002275) stock is about to trade ex-dividend in four days. The ex-dividend date is one business day before a company's record date, which is the date on wh
Guilin Sanjin (002275.SZ): 2023 equity distribution 10 distribution 3 yuan share registration date May 28
Gelonghui, May 20 | Guilin Sanjin (002275.SZ) announced that the company's 2023 equity distribution plan is to distribute RMB 3.000000 in cash (tax included) to all shareholders for every 10 shares based on the company's current total share capital excluding 587,568,600 shares after excluding 0 shares that have already been repurchased. The share registration date for this equity distribution is May 28, 2024, and the ex-dividend date is May 29, 2024.
Guilin Sanjin Pharmaceutical Co., Ltd.'s (SZSE:002275) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock?
Guilin Sanjin Pharmaceutical's (SZSE:002275) stock is up by 9.7% over the past three months. However, the company's financials look a bit inconsistent and market outcomes are ultimately driven by lo
No Data